Theodore Pasquali, MD
Ophthalmology · Lakewood, CANPI 1164682738
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (46.0%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Glaukos Corporation at 45.8% of the total.
Across 47 payments — averaging $70.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$2K
- Rxsight Inc$721
- NEW World Medical,inc.$237
- Tarsus Pharmaceuticals, Inc.$118
- Harrow Eye, LLC$108
- AbbVie$98
- plus $516 from 13 others
Across 21 payments — averaging $7996.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bausch Health US, LLC$168K
What the payments were for
- Consulting fees$66020%
- Speaking & faculty fees$1,52646%
- Food & beverage$1,11234%
- Gifts$191%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 2 | $1,520 |
| Rxsight Inc | 6 | $721 |
| NEW World Medical,inc. | 3 | $237 |
| Tarsus Pharmaceuticals, Inc. | 4 | $118 |
| Harrow Eye, LLC | 4 | $108 |
| AbbVie(2 entities) | 5 | $98 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $86 |
| Bausch & Lomb Americas Inc. | 4 | $80 |
| Nova Eye, Inc. | 1 | $52 |
| Sight Sciences, Inc. | 3 | $49 |
| Oyster Point Pharma, Inc. | 2 | $46 |
| Alcon | 2 | $41 |
| Thea Pharma Inc. | 2 | $40 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $39 |
| Omeros Corporation | 1 | $20 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Dompe US, Inc. | 1 | $18 |
| Biotissue Holdings Inc. | 1 | $13 |
| Aerie Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,317 in reported general payments places this provider in the 65th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 39 | $50,697 |
| RestasisCyclosporine | 21 | $26,317 |
| LumiganBimatoprost | 35 | $22,740 |
| RocklatanNetarsudil Mesylat/Latanoprost | 28 | $13,152 |
| Prednisolone Acetate | 353 | $11,077 |
| RhopressaNetarsudil Mesylate | 19 | $9,471 |
| Latanoprost | 594 | $9,151 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 20 | $7,339 |
| Ketorolac Tromethamine | 235 | $4,056 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 17 | $3,962 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 191 | $3,909 |
| Timolol Maleate | 75 | $3,884 |
| Ofloxacin | 238 | $2,955 |
| Travoprost | 13 | $1,421 |
| Brimonidine Tartrate | 66 | $965 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra | $80 | $50,69739 claims |
| AbbVieRestasis, Lumigan | $98 | $49,05756 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $12 | $22,62347 claims |
| AlconSimbrinza | $41 | $7,33920 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Lakewood
- Daniel SchwartzSan Francisco$8M
- Michael BerlinWest Hollywood$5.7M
- Gilbert KlimanMenlo Park$1.5M
- Kuldev SinghStanford$1.5M
- Raymond DouglasBeverly Hills$1.3M
- John AffeldtLoma Linda$1.1M
- Srinivas SaddaPasadena$1M
- Sheri RowenNewport Beach$1M
- Savak TeymoorianLaguna Hills$955K
- Andrew MoshfeghiLos Angeles$895K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.